Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 07:15 AM
November 2025
Join Anthony Derencius, PA-C for a concise, case-based update on steatotic liver disease—covering MASLD vs MetALD, how to interpret FibroScan (kPa/CAP), and when to use PEth to objectively quantify alcohol intake. Using a typical patient scenario (ultrasound steatosis, metabolic risk factors, daily wine), Anthony outlines practical steps for risk stratification, lifestyle and alcohol counseling, and monitoring advanced fibrosis, with clear thresholds to distinguish metabolic-predominant from alcohol-associated disease.
Related Webcast
Webcast: MASLD Basics With Ellie Gonyeau
August 2025
Join Ellie Gonyeau, NP, a GI and hepatology nurse practitioner at Beth Israel Deaconess Medical Center in Boston, for a foundational overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD. Presented through the GHAPP MASLD Community Network and sponsored by Madrigal Pharmaceuticals, this session covers the latest updates in MASLD nomenclature, diagnostic criteria, and non-invasive evaluation strategies. Ellie walks through the 2023 guidelines, emphasizing how MASLD is defined by hepatic steatosis in the presence of at least one metabolic risk factor—such as obesity, type 2 diabetes, hypertension, or dyslipidemia—and the importance of ruling out excessive alcohol use and other causes of chronic liver disease. Using real-world case examples like "JP", Ellie illustrates how to assess disease severity using tools such as FIB-4, FibroScan, and lab workups, while explaining when to consider specialty referral, further imaging, or liver biopsy. The talk also highlights the alarming rates of MASLD in high-risk populations, such as the Latin American community, and explores the disease's potential to silently progress to MASH, fibrosis, or cirrhosis. Whether you're in primary care, GI, or hepatology, this session provides critical insights on early detection, risk stratification, and guideline-based management of this increasingly prevalent condition.
Watch Now
Webcast: Lifestyle Management With Lavinia Iordache
September 2025
In this MASLD Community Network session, Lavinia Iordache uses a real-world case to show how to recognize and manage fatty liver disease with a lifestyle-first approach. She reviews the clinical pathway for at-risk patients (hypertension, dyslipidemia, diabetes, central adiposity), the role of non-invasive tests, and why indeterminate results often require a second modality. The talk clarifies alcohol distinctions and emphasizes that early staging and referral can change prognosis. Practical guidance includes culturally sensitive nutrition counseling (prioritizing the Mediterranean diet), realistic weight-loss targets, and tailored exercise plans—both aerobic and resistance training improve hepatic fat via different pathways. Lavinia also covers behavior strategies and cautions on one-size-fits-all tactics. You’ll leave with a clear, compassionate framework to help patients sustain lifestyle change, optimize cardiometabolic risk, and monitor disease progression over time.
Watch Now
Webcast: MASLD Pharmacotherapy With Tina Gregg
November 2025
In this educational presentation, Tina Gregg, NP-C breaks down the evolving pharmacotherapy landscape for MASLD and MASH, emphasizing a holistic, metabolic-centered approach to patient management. Tina reviews key treatment pillars—including weight loss, cardiovascular risk reduction, and direct NASH-targeted therapy—highlighting evidence-based strategies such as lifestyle modification, GLP-1 receptor agonists, pioglitazone, vitamin E, and the first FDA-approved therapy for MASH with F2–F3 fibrosis, resmetirom. She explains how these interventions improve hepatic histology, reduce fibrosis, and address comorbidities like diabetes and obesity. The session also explores data from the MAESTRO-NASH trial, drug-drug interaction considerations, and ongoing monitoring guidance for resmetirom. Whether you’re managing patients in hepatology, GI, or primary care, this discussion offers a comprehensive overview of current and emerging medical therapies shaping the future of metabolic liver disease care.
Watch Now
Webcast: Lifestyle Management With Erin Parkinson
July 2025
In this impactful session from the GHAPP MASLD Community Network, Erin Parkinson, APRN, explores the vital role of lifestyle modifications in the management of MASLD (Metabolic dysfunction-associated steatotic liver disease) and MASH (Metabolic dysfunction-associated steatohepatitis). Through the lens of a real-world case study, Erin illustrates how clinical tools like FIB-4 and FibroScan® can be used to assess fibrosis risk and guide interventions for patients presenting with metabolic syndrome and hepatic steatosis. With a focus on practical, personalized care, this presentation highlights how diet, exercise, and culturally sensitive counseling can meaningfully reduce hepatic fat, inflammation, and fibrosis—key factors in preventing progression to cirrhosis or hepatocellular carcinoma. Erin discusses the impact of processed foods, high-fructose corn syrup, and sedentary behavior, while offering actionable guidance on introducing Mediterranean diets, intermittent fasting, and realistic exercise goals tailored to individual readiness and barriers. Whether you're a hepatology specialist, primary care provider, or obesity medicine clinician, this talk delivers tools to better support patients with MASLD/MASH through sustainable behavioral change and longitudinal follow-up.
Watch Now
Webcast: MASLD vs MetALD With Maly Tiev
November 2025
In this educational session, Maly Tiev, NP from NYU Langone Health, explores the evolving understanding of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated alcohol-related liver disease (MetALD). Drawing on over 25 years of hepatology experience, she uses a real-world case to walk through the latest definitions, diagnostic criteria, and management strategies for patients with overlapping metabolic and alcohol-related liver disease. Maly explains how alcohol intake interacts with metabolic risk factors such as obesity, diabetes, and hypertension to accelerate fibrosis progression, and highlights the role of non-invasive testing—including FibroScan and the PEth test—in accurate diagnosis. The discussion also covers the clinical significance of F3 fibrosis, lifestyle interventions like the Mediterranean diet, and when to consider pharmacologic treatment such as resmetirom for patients with advanced disease. Watch to better understand how to identify, classify, and manage MASLD and MetALD in clinical practice.
Watch Now
Webcast: MASLD Pharmacotherapy With Sherona Bau
July 2025
In this dynamic and highly informative session, Sherona Bau, NP, presents a comprehensive overview of pharmacotherapy in MASLD and MASH, breaking down current treatment strategies and emerging therapies for patients with metabolic dysfunction-associated steatotic liver disease. This presentation, part of the MASLD/MASH Community Network, begins by contextualizing the recent nomenclature shift from NAFLD/NASH to MASLD/MASH and its clinical implications. Sherona explores lifestyle intervention targets, including Mediterranean diet, weight loss goals based on fibrosis stage, and the role of GLP-1 and GIP receptor agonists in improving liver health. She highlights the ESSENCE trial results for semaglutide, discusses the only FDA-approved therapy to date—resmetirom (Rezdiffra)—and explains its mechanism of action via thyroid hormone receptor beta activation. The session dives deep into efficacy data from the MAESTRO-NASH trial, side effect profiles, drug–drug interactions, and monitoring recommendations. She also previews a pipeline of promising agents in phase 2 and 3 trials—including tirzepatide (GLP-1/GIP), cotadutide (GLP-1/GR), pemvidutide (GLP-1/GIP), and retatrutide (GLP-1/GIP/GR)—offering insight into what’s next in the evolving treatment landscape. This is a must-watch for hepatology and endocrinology clinicians focused on the future of fatty liver management.
Watch Now
Webcast: MASLD Basics With Summer Collier
July 2025
Join Summer Collier, NP from UC San Diego Health, for an essential overview of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) in this GHAPP MASLD Community Network session. Designed for clinicians and healthcare professionals, this case-based talk covers the evolving nomenclature shift from NAFLD/NASH to MASLD/MASH, including key definitions, diagnostic criteria, and practical tools for identifying and managing patients with steatotic liver disease. Summer walks through foundational concepts like the role of hepatic steatosis, cardio-metabolic risk factors, and the importance of excluding significant alcohol use to establish a MASLD diagnosis. She also provides clinical insights into non-invasive fibrosis staging using FIB-4, FibroScan, elastography, and blood-based tests, as well as how to differentiate patients who may require hepatology referral or biopsy. Emphasizing the importance of early detection and risk stratification in primary care, this session highlights how fibrosis stage impacts prognosis, treatment planning, and long-term liver-related outcomes. For more educational sessions and MASLD tools — visit the GHAPP MASLD Community Network.
Watch Now
Webcast: MASLD Pharmacotherapy With Patrick Horne
September 2025
Join Patrick Horne, NP for a clear, clinic-ready overview of MASLD/MASH pharmacology—from the lifestyle backbone to cardiometabolic risk reduction and liver-directed therapies. Patrick breaks down where GLP-1 receptor agonists fit, reviews evidence and patient selection for vitamin E and pioglitazone, and spotlights resmetirom—the first FDA-approved THR-β agonist for non-cirrhotic MASH with F2–F3 fibrosis—including mechanism, key MAESTRO-NASH outcomes, common AEs (nausea/diarrhea), and practical drug–drug interactions. Walk away with a step-by-step approach to selecting therapy, setting measurable lifestyle goals, and using NITs to monitor response and guide duration—so you can confidently tailor treatment and improve outcomes.
Watch Now
Webcast: MASLD vs MetALD With Allysa Saggese
September 2025
In this MASLD Community Network session, Allysa Saggese, NP, from Weill Cornell Medicine, New York, walks through a real-world case to demystify the overlap between MASLD, MASH, and metabolic-alcohol related liver disease (MetALD). You’ll learn how to take a precise alcohol history, translate “standard drink” equivalents (≈14 g ethanol), and use objective biomarkers like PEth alongside FIB-4, FibroScan (kPa), ELF, CAP, and MRI elastography to stage disease accurately and catch discordant results. Allysa covers how alcohol can skew labs (ALT/AST, triglycerides, BP), why reducing/abstaining may change non-invasive testing thresholds, when to consider liver biopsy, and who qualifies for HCC surveillance. She also outlines treatment pillars—lifestyle optimization, cardiometabolic risk control, and appropriate pharmacotherapy (including where resmetirom fits and when to avoid it)—so clinicians can tailor care for patients spanning pure MASLD to MetALD. Watch to sharpen your staging, counseling, and monitoring strategy—and help patients make data-driven changes that improve outcomes.
Watch Now
Webcast: Non-Invasive Testing With Janet Gripshover
July 2025
In this in-depth and practical discussion, Janet Gripshover, NP from Cedars-Sinai in Los Angeles, explores the evolving role of non-invasive testing (NITs) in the diagnosis and risk stratification of MASLD (Metabolic dysfunction-associated steatotic liver disease) and MASH (Metabolic dysfunction-associated steatohepatitis). Drawing from real-world experience and a case study involving a 65-year-old patient with multiple cardiometabolic risk factors, she breaks down the latest 2025 approaches to fibrosis assessment—highlighting the use of FIB-4, ELF score, vibration-controlled transient elastography (FibroScan®), and MR elastography. Gryover also emphasizes how combining tests across modalities can improve accuracy and patient care while avoiding the risks of liver biopsy. Learn how liver stiffness, lab values, and clinical history all intersect to guide care and treatment decisions in patients with fatty liver disease. This session is part of the MASLD/MASH Community Network and is ideal for providers, specialists, and anyone interested in the forefront of liver disease management.
Watch Now